Cost effectiveness of early discharge after uncomplicated acute myocardial infarction

New England Journal of Medicine

Volumn 342, Issue 11, 2000, Pages 749-755

  Newby, L Kristin ^a   Eisenstein, Eric L ^a   Califf, Robert M ^a   Thompson, Trevor D ^a   Nelson, Charlotte L ^a   Peterson, Eric D ^a   Armstrong, Paul W ^b   Van De Werf, Frans ^c   White, Harvey D ^d   Topol, Eric J ^e   Mark, Daniel B ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d GREEN LANE HOSPITAL   (New Zealand)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; FEMALE; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESUSCITATION; SURVIVAL;

AGED; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LENGTH OF STAY; LIFE EXPECTANCY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TIME FACTORS; VALUE OF LIFE;

EID: 0034673750     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200003163421101     Document Type: Article

References (26)

1. Topol EJ, Burek K, O'Neill WW, et al. A randomized controlled trial of hospital discharge three days after myocardial infarction in the era of reperfusion. N Engl J Med 1988;318:1083-8.
2. Sanz G, Betriu A, Oller G, et al. Feasibility of early discharge after acute Q wave myocardial infarction in patients not receiving thrombolytic treatment. J Am Coll Cardiol 1993;22:1795-801.
3. Mark DB, Sigmon K, Topol EJ, et al. Identification of acute myocardial infarction patients suitable for early hospital discharge after aggressive interventional therapy: results from the Thombolysis and Angioplasty in Acute Myocardial Infarction Registry. Circulation 1991;83:1186-93.
4. Newby LK, Califf RM, Guerci A, et al. Early discharge in the thrombolytic era: an analysis of criteria for uncomplicated infarction from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) trial J Am Coll Cardiol 1996;27:625-32.
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. Data 3.0 user's manual. Williamstown, Mass.: TreeAge Software, 1996.
7. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with strepto-kinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24. [Erratum, N Engl J Med 1995;333:267.]
8. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
9. Eisenberg MS, Cummins RO, Larsen MP. Numerators, denominators, and survival rates: reporting survival from out-of-hospital cardiac arrest. Am J Emerg Med 1991;9:544-6.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
11. Mark DB. Medical economics in cardiovascular medicine. In: Topol EJ, ed. Textbook of cardiovascular medicine. Philadelphia: Lippincott-Raven, 1997:1033-61.
12. Tengs TO, Adams ME, Pliskin JS, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
13. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-23.
14. Mark DB, Harrington RA, Lincoff AM, et al. Cost effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST elevation acute coronary syndromes. Circulation 2000;101:366-71.
15. Mark DB, Cowper PA, Berkowitz SD, et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Circulation 1998;97:1702-7.
16. Topol EJ, Juni JE, O'Neill WW, et al. Exercise testing three days after onset of acute myocardial infarction. Am J Cardiol 1987;60:958-62.
17. Stratmann HG, Mark AL, Amato M, Wittry MD, Younis LT. Risk stratification with pre-hospital discharge exercise technetium-99m sestamibi myocardial tomography in men after acute myocardial infarction. Am Heart J 1998;136:87-93.
18. Pierard LA, Lancellotti P, Kulbertus HE. ST-segment elevation during dobutamine stress testing predicts functional recovery after acute myocardial infarction. Am Heart J 1999;137:500-11.
19. Jain A, Myers GH, Sapin PM, O'Rourke RA. Comparison of symptom-limited and low level exercise tolerance tests early after myocardial infarction. J Am Coll Cardiol 1993;22:1816-20.
20. McNeer JF, Wagner GS, Ginsburg PB, et al. Hospital discharge one week after acute myocardial infarction. N Engl J Med 1978;298:229-32.
21. Madsen EB, Hougaard P, Gilpin E, Pedersen A. The length of hospitalization after acute myocardial infarction determined by risk calculation. Circulation 1983;68:9-16.
22. Grines CL, Marsalese DL, Brodie BR, et al. Safety and cost-effectiveness of early discharge after primary angioplasty in low risk patients with acute myocardial infarction. J Am Coll Cardiol 1998;31:967-72.
23. Marciniak TA, Ellerbeck EF, Radford MJ, et al. Improving the quality of care for Medicare patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. JAMA 1998;279:1351-7.
24. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for Medicare patients with acute myocardial infarction: a four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-14.
25. Krumholz HM, Vaccarino V, Ellerbeck EF, et al. Determinants of appropriate use of angiotensin-converting enzyme inhibitors after acute myocardial infarction in persons age ≥65 years of age. Am J Cardiol 1997;79:581-6.
26. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 1998;280:623-9. [Erratum, JAMA 1999; 281:37.]